Drugs

Anti-Smoking Therapies: Is Harm Reduction a Viable Alternative to Smoking Cessation?
pp. 1041-1044(4)
Author: Zellweger J-P.

Antiepileptogenic Agents: How Close Are We?
pp. 1045-1055(11)
Authors: Temkin N.R.; Jarell A.D.; Anderson G.D.

Intraperitoneal Drug Delivery of Antineoplastics
pp. 1057-1065(9)
Author: Markman M.

Pharmacotherapy of Ectoparasitic Infections
pp. 1067-1088(22)
Authors: Roos T.C.; Alam M.; Roos S.; Merk H.F.; Bickers D.R.

Menière’s Disease: Pathophysiology and Treatment
pp. 1089-1102(14)
Authors: Thai-Van H.; Bounaix M-J.; Fraysse B.

Pursuit of Optimum Outcomes in Ovarian Cancer: Methodological Approaches to Therapy
pp. 1103-1120(18)
Authors: Gibbs D.D.; Gore M.E.

Caspofungin
pp. 1121-1129(9)
Authors: Keating G.M.; Jarvis B.

Caspofungin: A Viewpoint by Ben E. De Pauw
pp. 1130-1131(2)
Author: De Pauw B.E.

Caspofungin: A Viewpoint by Helen Leather and John Wingard
pp. 1130-1131(2)
Authors: Leather H.; Wingard J.

Parecoxib (Parecoxib Sodium)
pp. 1133-1141(9)
Authors: Cheer S.M.; Goa K.L.

Parecoxib: A Viewpoint by Daniel Carr
pp. 1142-1143(2)
Author: Carr D.

Parecoxib: A Viewpoint by Edward C. Huskisson
pp. 1142-1143(2)
Author: Huskisson E.C.

Valganciclovir
pp. 1145-1150(6)
Authors: Curran M.; Noble S.

Valganciclovir: A Viewpoint by Sharon Walmsley
pp. 1151-1152(2)
Author: Walmsley S.

Valganciclovir: A Viewpoint by Mark D. Pescovitz
pp. 1151-1152(2)
Author: Pescovitz M.D.

Ganciclovir: An Update of its Use in the Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients
pp. 1153-1183(31)
Authors: McGavin J.K.; Goa K.L.

Reviparin: A Review of its Efficacy in the Prevention and Treatment of Venous Thromboembolism
pp. 1185-1209(25)
Authors: Wellington K.; McClellan K.; Jarvis B.

Perindopril/Indapamide 2/0.625 mg/day: A Review of its Place in the Management of Hypertension
pp. 1211-1229(19)
Authors: Matheson A.J.; Cheer S.M.; Goa K.L.